ARHGAP11A and nonpapillary renal cell carcinoma: High ARHGAP11A level was correlated with shorter overall survival (OS) for ccRCC patients (HR 2.040, 95% CI 1.646–3.417), especially for patients with higher AJCC stage (HR 1.863, 95% CI 1.340–3.323), T stage (HR 1.896, 95% CI 1.335–3.557), and Fuhrman grade (HR 1.782, 95% CI 1.289–2.994).